Table 5.
Effect of additional variants in APOE vicinity on AD risk in the ADGC data. Analysis restricted to individuals of European descent for which we have imputed genotypes
| Fully Adjusted Model | Model without ε4 dosage | Model without ε2 | |||||
|---|---|---|---|---|---|---|---|
| SNP | BP | Estimate Pr(> |z|) | Estimate | Pr(> |z|) | Estimate | Pr(> |z|) | |
| rs11668861 | 19:45380970 | 0.930 | 0.076 | 0.886 | 0.003 | 0.984 | 0.681 |
| rs6859 | 19:45382034 | 0.928 | 0.065 | 0.889 | 0.003 | 0.893 | 0.005 |
| rs3852860 | 19:45382966 | 0.981 | 0.635 | 0.944 | 0.159 | 0.967 | 0.418 |
| rs3852861 | 19:45383061 | 0.979 | 0.612 | 0.943 | 0.148 | 0.966 | 0.401 |
| rs438811 | 19:45416741 | 0.812 | 0.395 | 2.733 | 1.30E–19 | 0.601 | 2.61E–09 |
| rs12721046 | 19:45421254 | 1.070 | 0.361 | 1.426 | 4.85E–08 | 1.097 | 0.210 |
| rs12721051 | 19:45422160 | 1.189 | 0.092 | 1.912 | 2.23E–16 | 1.232 | 0.042 |
| rs56131196 | 19:45422846 | 1.191 | 0.087 | 1.905 | 2.49E–16 | 1.232 | 0.041 |
| rs4420638 | 19:45422946 | 1.189 | 0.089 | 1.900 | 2.89E–16 | 1.228 | 0.043 |